An overview of the in vitro test results on several human tumour cell lines of several series of organotin compounds synthesized at the Free University of Brussels VUB. Several compounds exhibit excellent antitumour activities. In vivo screening also gave very promising results.
Antitumour activity of diorganotin dicarboxylates Diorganotin derivatives of substituted salicylic acids (2) were also synthesized. Here, two types of compounds can be made depending on the molar ratio carboxylic acid:diorganotin oxide used. When a 2:1 molar ratio is used, the expected diorganotin dicarboxylate is formed. The structure of .diethyltin bis(2-methylthio-3-pyridinecarboxylate)(5) is shown in fig. 2 .
The di-n-butyltin compounds are again the most active ones. For instance, di-n-butyltin bis (4- Other series of organotin compounds were synthesized that were found more active than these last ones but they have first to be patented before more can be disclosed about them.
In vivo activity of organotin compounds
The the toxicity profiles in vivo in mice and the antitumour activity in tumour-bearing mice were screened(8) for five organotin compounds that were found especially active in vitro: triphenyltin 5- sulfosalicylate (1), triphenyltin 5-aminosalicylate (2), triphenyltin 4-fluorobenzoate (3), tri-n-butyltin 2,6-difluorobenzoate (4) and di-n-butyltin bis(2,5-dihydroxybenzoate) (5) . In vivo (table), compound 1 was most toxic mainly through paralysis. At their maximum tolerated dosis (MTD) for a single administration, compounds 1,2, 3 and 4 are inactive against murine colon carcinoma Colon 26. At a single administration, compound 5 was the most active with a Test/Control ratio (T/C) below 0.6 and Growth Delay Factor (GDF) above 1.0, their respective cut-off levels for sensitivity. 
